• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017 - Product Image

Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017

  • Published: March 2013
  • Region: Global
  • 148 Pages
  • Markets and Markets

FEATURED COMPANIES

  • Amgen, Inc.
  • Biogen Idec, Inc.
  • Dna2.0, Inc. (U.S.)
  • Genentech, Inc.
  • Johnson & Johnson
  • Morphosys
  • MORE

Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications.

The global protein engineering technologies market (2012-2017) report analyses the market by technology, products, applications, and geography. It also includes recent technology trends, patents, and funding analysis. In addition, it also covers factors driving and restraining the growth of the market and market scenario in the U.S., Europe, Asia, and Rest of the World (RoW).

The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of READ MORE >

1 Introduction

1.1 Key Take- Aways

1.2 Report Scope

1.3 Report Segmentation

1.4 Research Methodology

1.5 Key Data Points From Primary And Secondary Sources



2 Executive Summary



3 Protein Engineering Technologies – Landscape Analysis

3.1 Technology - Introduction

3.2 Technology – Evolution

3.3 Market Segmentation

3.4 Protein And Antibody Engineering Technologies – Overview

3.4.1 Sequence Modification

3.4.2 Glycosylation

3.4.3 Pegylation

3.4.4 Display Technologies

3.4.5 Humanization Technology

3.4.6 Hybrid Technology

3.4.7 Production Systems

3.4.8 Mapping Of Protein Production Systems

3.4.9 Emerging Production Systems

3.5 Protein Engineering – Technology Value Chain Analysis



4 Applications

4.1 Therapeutic Development – Overview

4.1.1 Insulin Analogs

4.1.2 Monoclonal Antibodies

4.1.3 Therapeutic Development - Erythropoietin & Others

4.2 Diagnostics

4.3 Research – Meganuclease Engineering/Zfp & Talens Engineering



5 Market Landscape Analysis

5.1 Global Protein Engineering Market Forecast

5.1.1 Introduction

5.1.2 Global Protein Engineering Market Forecast, By Geography

5.1.3 Global Protein Engineering Market Forecast, By Product

5.1.4 Global Protein Engineering Market Forecast, By Application

5.1.5 Global Protein Engineering Market Forecast, By Technology

5.2 Market Dynamics - Overview

5.2.1 Drivers – Description

5.2.2 Drivers’ Impact – Timeline

5.2.3 Restraints – Description

5.2.4 Restraints Impact – Timeline

5.2.5 Opportunities – Description

5.2.6 Threats – Description

5.2.7 Pestle Analysis

5.3 Market Segmentation, By Product

5.3.1 Insulin Analogs

5.3.1.1 Insulin Analog Market

5.3.1.2 Insulin Analog Market, By Geography

5.3.1.3 Market Share Analysis

5.3.2 Modified Epo

5.3.2.1 Modified Epo Market

5.3.2.2 Modified Epo Market, By Geography

5.3.3 Monoclonal Antibodies (Mab)

5.3.3.1 Monoclonal Antibodies Market

5.3.3.2 Monoclonal Antibodies Market, By Geography

5.3.3.3 Monoclonal Antibodies Market, By Application

5.3.3.4 Major Products In The Market

5.4 Other Proteins

5.4.1 Other Proteins Market

5.4.2 Other Proteins Market, By Geography

5.4.3 Diagnostic Proteins, By Geography



6 Geographic Analysis

6.1 North America

6.2 Europe

6.3 Asia

6.4 Row



7 Technology And Product Portfolio

7.1 Proprietary Technology Platforms

7.2 Product Pipeline Analysis Of Key Players



8 Competitive Landscape

8.1 Introduction

8.2 Porter’S Five Force Analysis

8.3 Mergers & Acquisitions, 2009 – 2012

8.4 Partnerships & Collaborations, 2012 - 2013

8.5 New Product Launch, 2010 – 2012



9 Analyst Insights And Recommendation

9.1 Strategic Recommendations



10 Company Profiles

10.1 Genentech, Inc.

10.2 Amgen, Inc.

10.3 Biogen Idec, Inc.

10.4 Novartis Ag

10.5 Glaxo Smithkline Plc

10.6 Eli Lilly & Co

10.7 Bristol Myers Squibb Co.

10.8 Johnson & Johnson

10.9 Merck & Co., Inc.

10.10 Sanofi

10.11 Pfizer, Inc.

10.12 Regeneron Pharmaceuticals, Inc.

10.13 Eleven Biotherapeutics (U.S.)

10.14 Toolgen, Inc. (Korea)

10.15 Dna2.0, Inc. (U.S.)

10.16 Avidbiotics Corp. (U.S.)

10.17 Sigma-Aldrich Corp. (U.S.)

10.18 Xencor Inc.

10.19 Morphosys

List Of Tables



Table - 1 Global Protein Engineering Market Revenue, 2012 – 2017 ($Billion)

Table - 2 Global Protein Engineering Market, By Geography, 2012 – 2017 ($Billion)

Table - 3 Global Protein Engineering Market, By Product, 2012 – 2017 ($Billion)

Table - 4 Global Protein Engineering Market, By Application, 2012 – 2017 ($Billion)

Table - 5 Global Protein Engineering Market, By Technology, 2012 – 2017 ($Billion)

Table - 6 Insulin Analogs Market, By Geography, 2012 – 2017 ($Billion)

Table - 7 Modified Epo Market, By Geography, 2012 – 2017 ($Billion)

Table - 8 Mab Market, By Geography, 2012 – 2017 ($Billion)

Table - 9 Mab Market, By Application, 2012 – 2017 ($Billion)

Table - 10 Other Proteins Market, By Geography, 2012 – 2017 ($Billion)

Table - 11 Diagnostic Proteins Market, By Geography, 2012 – 2017 ($Billion)

List Of Figures

Fig - 1 Global Protein Engineering Market, 2012 – 2017 ($Billion)

Fig - 2 Global Protein Engineering Market, 2012 – 2017 ($Billion)

Fig - 3 Global Protein Engineering Market, By Geography, 2012 (%)

Fig - 4 Growth Rate, By Geography, 2012 – 2017

Fig - 5 Global Protein Engineering Market By Geography, 2012 – 2017 ($Billion)

Fig - 6 Global Protein Engineering Market, By Product, 2012 (%)

Fig - 7 Growth Rate, By Product, 2012 – 2017

Fig - 8 Global Protein Engineering Market, By Product, 2012 – 2017 ($Billion)

Fig - 9 Global Protein Engineering Market, By Application, 2012 (%)

Fig - 10 Growth Rate, By Application, 2012 – 2017

Fig - 11 Global Protein Engineering Market, By Application, 2012 - 2017 ($Billion)

Fig - 12 Global Protein Engineering Market, By Technology, 2012 (%)

Fig - 13 Growth Rate, By Technology, 2012 – 2017

Fig - 14 Global Protein Engineering Market, By Technology, 2012 – 2017 ($Billion)

Fig - 15 Market Share Analysis

Fig - 16 Insulin Analogs Market, By Geography, 2012

Fig - 17 Insulin Analogs Market, By Geography, 2012 – 2017 ($Billion)

Fig - 18 Market Share Analysis, Key Players, 2012

Fig - 19 Market Share Analysis Of Epo, By Product, 2012

Fig - 20 Modified Epo Market, By Geography, 2012

Fig - 21 Modified Epo Market, By Geography, 2012 – 2017 ($Billion)

Fig - 22 Market Share Analysis Of Engineered Therapeutic Proteins, By Product, 2012

Fig - 23 Mab Market, By Geography, 2012

Fig - 24 Mab Market, By Geography, 2012 – 2017 ($Billion)

Fig - 25 Mab Market,By Application, 2012

Fig - 26 Mab Market, By Application, 2012 – 2017 ($Billion)

Fig - 27 Market Share Analysis Of Other Proteins, 2012

Fig - 28 Other Proteins Market, By Geography, 2012

Fig - 29 Other Proteins Market, By Geography, 2012 – 2017 ($Billion)

Fig - 30 Diagnostic Proteins Market, By Geography, 2012

Fig - 31 Diagnostic Proteins Market, By Geography, 2012 – 2017 ($Billion)

Fig - 32 Product Pipeline Of Key Players

Fig - 33 Growth Strategies

Fig - 34 Amgen, Inc., Total Revenue

Fig - 35 Biogen Idec, Inc., Total Revenue

Fig - 36 Novartis Ag, Total Revenue

Fig - 37 Glaxo Smithkline Plc, Total Revenue

Fig - 38 Eli Lilly & Co., Total Revenue

Fig - 39 Bristol Myers Squibb Co., Total Revenue

Fig - 40 Johnson & Johnson , Total Revenue

Fig - 41 Merck & Co., Inc., Total Revenue

Fig - 42 Sanofi , Total Revenue

Fig - 43 Pfizer, Inc., Total Revenue

Fig - 44 Regeneron Pharmaceuticals, Inc. , Total Revenue

- Amgen, Inc.

- Avidbiotics Corp. (U.S.)

- Biogen Idec, Inc.

- Bristol Myers Squibb Co.

- Dna2.0, Inc. (U.S.)

- Eleven Biotherapeutics (U.S.)

- Eli Lilly & Co

- Genentech, Inc.

- Glaxo Smithkline Plc

- Johnson & Johnson

- Merck & Co., Inc.

- Morphosys

- Novartis Ag

- Pfizer, Inc.

- Regeneron Pharmaceuticals, Inc.

- Sanofi

- Sigma-Aldrich Corp. (U.S.)

- Toolgen, Inc. (Korea)

- Xencor Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos